×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma Cancer

Kristie L. Kahl
Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.
 
Jessica Skarzynski
As researchers recently discovered, outcomes for patients with diffuse large B-cell lymphoma are just as good when the number of chemotherapy cycles is reduced.
Shira Zwebner
How to conquer the fear of your own body, one step at a time.
WENDY S . HARPHAM, M.D.
WE SURVIVORS ARE INUNDATED with the message: “Be hopeful!” Unfortunately, that universal rallying cry doesn’t help us know how to find hope or what to hope for.
 
Beth Fand Incollingo
PAUL ALLEN, A COFOUNDER of Microsoft, died of the blood cancer non-Hodgkin lymphoma on Oct. 16.
 
Kristie L. Kahl
Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.
Felicia Mitchell
Especially during holiday seasons, we remember loved ones who are not with us. Even long after they have passed, we can cherish old memories and even make new ones with the help of social media. Recently I learned something sweet about my brother John, who died of Hodgkin's lymphoma decades ago, from a high school friend I never knew about.
Kristie L. Kahl
Treatment with Xarelto (rivaroxaban) may reduce the risk for developing blood clots during active treatment with a systemic therapy like chemotherapy, according to results from the CASSINI trial.
Brielle Benyon
The Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) – the first biosimilar of Rituxan (rituximab) – to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL).
Katie Kosko
Jeff Young, D.V.M., refused to let cancer stop him from living.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other